UNION therapeutics Research Services ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 26.0% 6.4% 5.2% 5.7%  
Credit score (0-100)  0 3 36 42 39  
Credit rating  N/A B BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 597 492 258  
Gross profit  0.0 0.0 597 492 258  
EBITDA  0.0 0.0 226 275 19.6  
EBIT  0.0 0.0 226 275 19.6  
Pre-tax profit (PTP)  0.0 0.0 220.2 268.5 18.4  
Net earnings  0.0 0.0 220.2 268.5 18.4  
Pre-tax profit without non-rec. items  0.0 0.0 220 269 18.4  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 40.0 260 529 547  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0.0 40.0 745 748 623  

Net Debt  0.0 -40.0 -588 -622 -462  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 597 492 258  
Net sales growth  0.0% 0.0% 0.0% -17.6% -47.6%  
Gross profit  0.0 0.0 597 492 258  
Gross profit growth  0.0% 0.0% 0.0% -17.6% -47.6%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 -678.3 -711.6  
Balance sheet total (assets)  0 40 745 748 623  
Balance sheet change%  0.0% 0.0% 1,762.5% 0.4% -16.7%  
Added value  0.0 0.0 226.3 952.9 731.2  
Added value %  0.0% 0.0% 37.9% 193.5% 283.2%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 -1.0 -2.0  
EBIT trend  0.0 0.0 1.0 2.0 3.0  

Profitability 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 37.9% 55.8% 7.6%  
EBIT %  0.0% 0.0% 37.9% 55.8% 7.6%  
EBIT to gross profit (%)  0.0% 0.0% 37.9% 55.8% 7.6%  
Net Earnings %  0.0% 0.0% 36.9% 54.5% 7.1%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 36.9% 54.5% 7.1%  
Pre tax profit less extraordinaries %  0.0% 0.0% 36.9% 54.5% 7.1%  
ROA %  0.0% 0.0% 57.7% 36.8% 2.9%  
ROI %  0.0% 0.0% 150.8% 69.6% 3.6%  
ROE %  0.0% 0.0% 146.7% 68.1% 3.4%  

Solidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 100.0% 34.9% 70.7% 87.8%  
Relative indebtedness %  0.0% 0.0% 81.2% 44.5% 29.4%  
Relative net indebtedness %  0.0% 0.0% -17.3% -81.8% -149.7%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -259.9% -226.4% -2,358.9%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 1.5 3.4 8.2  
Current Ratio  0.0 0.0 1.5 3.4 8.2  
Cash and cash equivalent  0.0 40.0 588.2 621.6 462.2  

Capital use efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 95.8 93.5 131.2  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 124.7% 151.9% 241.3%  
Net working capital  0.0 40.0 260.2 528.7 547.1  
Net working capital %  0.0% 0.0% 43.6% 107.4% 211.9%  

Employee efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0